{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:01:14Z","timestamp":1790917274304,"version":"4.1.0"},"reference-count":31,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor.\r\nMaterials and methods. Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients with chronic hepatitis D and compensated cirrhosis, in monotherapy and combination with pegylated interferon alpha-2a (PEG-IFN).\r\nResults. Monotherapy with bulevirtide for 24 weeks in the MYR202 study in 46 patients with compensated liver cirrhosis demonstrated: 1) a high rate of virological (100%) and biochemical response (alanine aminotransferase normalization rate  45.7%), 2) superiority of bulevirtide in efficacy over the control group (tenofovir), 3) comparability of treatment efficacy in patients with and without cirrhosis, 4) no progression of liver fibrosis with elastometry in most patients.\r\nTreatment with bulevirtide in monotherapy and combination with PEG-IFN for 48 weeks in 10 patients with compensated liver cirrhosis in the MYR203 study was accompanied by a high rate of virological response (80%) and normalization of alanine aminotransferase (70%).\r\nBulevirtide was well tolerated, there was no deterioration in tolerability compared with patients without cirrhosis, there were no serious adverse events and cases of treatment cancellation due to adverse events.\r\nConclusion. Bulevirtide is recommended as the first line of treatment for chronic hepatitis D in patients with compensated cirrhosis in monotherapy and combination with PEG-IFN.<\/jats:p>","DOI":"10.26442\/00403660.2021.11.201163","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:54:04Z","timestamp":1643795644000},"page":"1290-1299","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis"],"prefix":"10.26442","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-1216","authenticated-orcid":false,"given":"Pavel O.","family":"Bogomolov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6815-6015","authenticated-orcid":false,"given":"Vladimir T.","family":"Ivashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-3466","authenticated-orcid":false,"given":"Alexey O.","family":"Bueverov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-564X","authenticated-orcid":false,"given":"Igor V.","family":"Maev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-7342","authenticated-orcid":false,"given":"Olga I.","family":"Sagalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-4750","authenticated-orcid":false,"given":"Snezhana S.","family":"Sleptsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-4747","authenticated-orcid":false,"given":"Nikolay D.","family":"Yushuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-3231","authenticated-orcid":false,"given":"Denis A.","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-1874","authenticated-orcid":false,"given":"Konstantin V.","family":"Zhdanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-9293","authenticated-orcid":false,"given":"Vladimir P.","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1033"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz023"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2019.03.009"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i32.4580"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026571"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bremer B, Anastasiou O, Hardtke S, et al. Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study. J Hepatol. 2020;73(Suppl. 1):S868.","DOI":"10.1016\/S0168-8278(20)32177-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104995"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1613-1622.2005"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.030"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.013"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.011"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.744"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.20953\/1729-9225-2020-4-153-162"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01400-1"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov P, et al. Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with Peg-Interferon alpha 2a in patients with chronic HBV\/HDV co-infection. Hepatology. 2018;68:S11A.","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14356"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S235550"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.022"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.032"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.014"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323888"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.003"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14950"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14967"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/99543\/73009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/99543\/73009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:54:20Z","timestamp":1643795660000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/99543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2021.11.201163","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}